Please use another Browser
It looks like you are using a browser that is not fully supported. Please note that there might be constraints on site display and usability. For the best experience we suggest that you download the newest version of a supported browser:Continue with the current browser
A recent index from U.S. News and World report ranked America 18th in Quality of Life.
Among America’s domestic challenges, the country now spends significantly more on healthcare than every other high-income nation but has lower life expectancy and worse overall health.
Additionally, infrastructure needed to support growing, high-density population centers isn’t keeping pace with demand. The return of Americans to cities is creating a variety of challenges, including traffic congestion, lack of energy productivity, and environmental problems.
To improve healthcare, Siemens is focused on providing lifesaving health technology and driving breakthrough medical innovations.
To develop the smart cities of the future, Siemens is pioneering intelligent infrastructure.
Siemens Healthineers’ Molecular Diagnostics team is advancing innovation in the world of molecular testing – including the fight against the Zika virus.
Zika has been linked to a number of harmful impacts – even birth defects such as microcephaly.
Siemens invested in research and development to innovate Zika detection technology, supporting physicians in their efforts to innovate an assay for the qualitative detection of the Zika virus in RNA (ribonucleic acid). Last year its new molecular testing kit for the Zika virus was granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).*
*The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit has been authorized by FDA under an EUA for use by authorized Laboratories only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens. This test has not been FDA cleared or approved. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
By 2050, two-thirds of the world’s population will live in cities. With current U.S. infrastructure earning a D+ grade by The American Society of Civil Engineers, the U.S. needs to improve its infrastructure with smart solutions to ensure the economic success and longevity of cities across America. The answer is building smarter infrastructure.
In Seattle, Siemens is integrating traffic management systems across the city’s urban areas, enhancing real-time traffic alert and control. Using software, Seattle will be able to link traffic planning and control systems in order to take better advantage of its existing road infrastructure, lessen the impact of major traffic incidents, better manage traffic around large events such as football games and reduce overall congestion.